Trial Profile
Neoadjuvant Sintilimab (PD-1 Antibody)-Chemotherapy and Concurrent Sintilimab-chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma: a Single-arm, Phase 2 Clinical Trial
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Sintilimab (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- 17 Aug 2018 New trial record